Catalent, Inc. (NYSE:CTLT) Director Uwe Roehrhoff purchased 7,500 shares of the firm’s stock in a transaction dated Tuesday, November 21st. The stock was bought at an average cost of $39.22 per share, with a total value of $294,150.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Shares of Catalent, Inc. (NYSE CTLT) traded up $0.01 during trading on Wednesday, hitting $38.92. The company had a trading volume of 545,268 shares, compared to its average volume of 916,212. Catalent, Inc. has a 52 week low of $22.94 and a 52 week high of $43.39. The company has a current ratio of 2.91, a quick ratio of 2.49 and a debt-to-equity ratio of 2.01. The company has a market cap of $5,170.00, a price-to-earnings ratio of 26.92, a price-to-earnings-growth ratio of 2.47 and a beta of 1.49.

Catalent (NYSE:CTLT) last announced its earnings results on Monday, November 6th. The company reported $0.21 EPS for the quarter, beating the consensus estimate of $0.20 by $0.01. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The company had revenue of $543.90 million for the quarter, compared to analyst estimates of $490.75 million. During the same quarter in the prior year, the company earned $0.16 EPS. The firm’s revenue for the quarter was up 23.0% compared to the same quarter last year. analysts predict that Catalent, Inc. will post 1.46 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Catalent, Inc. (CTLT) Director Buys $294,150.00 in Stock” was posted by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.watchlistnews.com/catalent-inc-ctlt-director-buys-294150-00-in-stock/1720449.html.

Several brokerages have recently weighed in on CTLT. ValuEngine cut Catalent from a “buy” rating to a “hold” rating in a research note on Monday, October 2nd. BidaskClub cut Catalent from a “buy” rating to a “hold” rating in a research note on Tuesday, November 14th. Needham & Company LLC reissued a “hold” rating on shares of Catalent in a research note on Monday, October 23rd. Wells Fargo & Company increased their price target on Catalent from $39.00 to $43.00 and gave the company an “outperform” rating in a research note on Wednesday, September 20th. Finally, Bank of America Corporation reissued a “buy” rating and issued a $45.00 price target (up previously from $40.00) on shares of Catalent in a research note on Wednesday, September 20th. Five investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $42.11.

A number of large investors have recently made changes to their positions in CTLT. Zions Bancorporation bought a new position in Catalent in the third quarter worth approximately $100,000. Acrospire Investment Management LLC boosted its holdings in Catalent by 72.2% in the second quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock worth $109,000 after acquiring an additional 1,300 shares in the last quarter. Quantbot Technologies LP boosted its holdings in Catalent by 110.7% in the second quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock worth $120,000 after acquiring an additional 1,804 shares in the last quarter. Fortaleza Asset Management Inc. bought a new position in Catalent in the third quarter worth approximately $164,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Catalent by 12.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,043 shares of the company’s stock worth $177,000 after acquiring an additional 559 shares in the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.